Key facts
- Seed Therapeutics’s last known valuation is $130.0M (Aug 2025).
- It has raised $50.0M; the latest was Later Stage VC ($30.0M) in Aug 2025.
- Notable investors include Endless Frontier Labs, Eisai, Eli Lilly.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Seed Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Seed Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Seed Therapeutics
Operator of a biotechnology company intended to develop targeted protein degradation therapeutics for diseases with limited treatment options. The company specializes in research and development and is engaged in harnessing and engineering molecules that use molecular glues to attack protein targets, enabling the oncology and neurodegeneration sectors to tackle previously undruggable diseases with novel drug candidates.
- Sector
- Healthcare
- HQ
- King of Prussia, PA, United States
- Founded
- 2019
- Employees
- 22
- Website
- seedtherapeutics.com/
- Ownership
- Privately Held (backing)
Seed Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seed Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seed Therapeutics in its N-PORT filings yet. We sweep new filings monthly.